×

Nationality: Italian | Year of Birth: 1974

Giovanni Di Napoli was appointed executive director and CEO at Cosmo Pharmaceuticals NV as of May 2024.

Giovanni Di Napoli is an accomplished Healthcare Executive with over 20 years of experience in Life Sciences spanning entrepreneurial ventures and corporate environments. During my tenure leading Medtronic’s Gastrointestinal (GI) Operating Unit (OU), he spearheaded remarkable growth from a two-product niche OU to a global OU encompassing approximately 20 products across three portfolios. This expansion significantly contributed to Medtronic’s $32 billion revenue, achieved through the implementation of a direct sales model, team restructuring, internal innovation, and strategic acquisitions, all aligned with the overarching vision of advancing patient health worldwide.

As President of the GI OU, he helped to pioneer the integration of AI into the GI field, earning recognition from Forbes Magazine for innovative contributions in March ’21 as a co-author of the article “The brave new world of artificial intelligence: dawn of a new era.”

Moreover, he led the acquisition of the PillCam business worth approximately $1 billion as part of the larger acquisition of Covidien by Medtronic.

With oversight of all GI operations, including P&L management and employee well-being across various departments such as Sales, Marketing, Quality, Business Development, Research & Development, Clinical, Regulatory, and among others, he prioritized diversity and inclusion, achieving a 42.4% diverse representation, consistently surpassing corporate standards.

Beyond his professional endeavors, Giovanni is committed to raising awareness of colon and esophageal cancer through collaborations with the Colon Cancer Alliance and Esophageal Cancer Association. Additionally, he contribute to the public community as part of Medtronic’s STEM project and personally support children’s education initiatives. Giovanni has received recognition such as the ASGE Crystal Award for contributions to the field of GI and regularly participate as a speaker at conferences globally, including in Silicon Valley and medical device and tech summits.

×

Nationality: Russian/USA | Year of Birth: 1982

Svetlana Sigalova was appointed Chief Financial Officer of Cosmo, effective November 11, 2024.

Svetlana brings a wealth of experience from senior financial roles at global pharmaceutical and biotech companies. As Vice President of Commercial Finance at Moderna, she led financial operations for over $6 billion in global sales, developing financial infrastructure and planning systems that were pivotal in Moderna’s rapid growth during the pandemic.

Prior to Moderna, Svetlana held senior finance leadership positions at Alexion Pharmaceuticals and Vertex Pharmaceuticals, where she managed multibillion-dollar revenue streams, built high-performance finance teams, and drove operational efficiency.